Qiagen N.V.

Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
  • TickerA2DKCH
  • ISINNL0012169213
  • SectorPharmaceuticals & Biotechnology
  • CountryNetherlands

Analysts

Michael Waterhouse

Improving Underlying Growth Supports Stronger Quarter for Qiagen, but Shares Look Fairly Valued

We plan to modestly boost our top-line forecast for Qiagen after the company reported slightly stronger-than-expected underlying 6% constant-currency revenue growth, or 8% growth when excluding the firm’s still struggling U.S. HPV business. Profitability remains a bit below our forecast, however, so these offsetting factors leave our fair value estimate unchanged. We already anticipated accelerating sales in our model thanks to improved performance in a number of product categories and diminishi...

Michael Waterhouse

Improving Underlying Growth Supports Stronger Quarter for Qiagen, but Shares Look Fairly Valued

We plan to modestly boost our top-line forecast for Qiagen after the company reported slightly stronger-than-expected underlying 6% constant-currency revenue growth, or 8% growth when excluding the firm’s still struggling U.S. HPV business. Profitability remains a bit below our forecast, however, so these offsetting factors leave our fair value estimate unchanged. We already anticipated accelerating sales in our model thanks to improved performance in a number of product categories and diminishi...

ValuEngine Rating and Forecast Report for QGEN

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. ValuEngine`s three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. Consensus EPS trend and Earnings Surprise statistics provide additional insights. Also, ValuEngine recommendation, Forecast analysis, Past performance, Evaluation and rankings, Comparison to industry, Comparison with peers, Analyst opinions, EPS consensus expectations, Company profil...

Michael Waterhouse

Qiagen Posts Encouraging Third Quarter; No Change to Our Fair Value Estimate

Qiagen reported strong third-quarter results that give us more confidence that management can attain its growth and margin expansion goals, but we’re leaving our fair value estimate and no-moat rating unchanged. When adjusted for stock repurchases, management’s preliminary outlook for 6% to 7% revenue growth and an adjusted EPS of $1.25 to $1.27 is close to our current forecast since we already incorporate a slight growth acceleration and additional margin expansion in our model. Qiagen’s growth...

Michael Waterhouse

Qiagen Posts Encouraging Third Quarter; No Change to Our Fair Value Estimate

Qiagen reported strong third-quarter results that give us more confidence that management can attain its growth and margin expansion goals, but we’re leaving our fair value estimate and no-moat rating unchanged. When adjusted for stock repurchases, management’s preliminary outlook for 6% to 7% revenue growth and an adjusted EPS of $1.25 to $1.27 is close to our current forecast since we already incorporate a slight growth acceleration and additional margin expansion in our model. Qiagen’s growth...

Remi Ramadou

QIAGEN NV- Rating report

Qiagen is a provider of innovative sample & assay technologies. The company’s automated systems and consumable products allow customers to transform raw biological amples into valuable molecular insights. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample, such as blood or tissue as well as plants and other samples that contain biological materials. Assay technologies are then used to amplify, enrich and provide results for analysis, such as the DNA of a virus or a mutation of a gene contained in a cancer cell, and these are supported by a portfolio of bio...

Michael Waterhouse

Improving Underlying Growth Supports Stronger Quarter for Qiagen, but Shares Look Fairly Valued

We plan to modestly boost our top-line forecast for Qiagen after the company reported slightly stronger-than-expected underlying 6% constant-currency revenue growth, or 8% growth when excluding the firm’s still struggling U.S. HPV business. Profitability remains a bit below our forecast, however, so these offsetting factors leave our fair value estimate unchanged. We already anticipated accelerating sales in our model thanks to improved performance in a number of product categories and diminishi...

Michael Waterhouse

Improving Underlying Growth Supports Stronger Quarter for Qiagen, but Shares Look Fairly Valued

We plan to modestly boost our top-line forecast for Qiagen after the company reported slightly stronger-than-expected underlying 6% constant-currency revenue growth, or 8% growth when excluding the firm’s still struggling U.S. HPV business. Profitability remains a bit below our forecast, however, so these offsetting factors leave our fair value estimate unchanged. We already anticipated accelerating sales in our model thanks to improved performance in a number of product categories and diminishi...

Michael Waterhouse

Qiagen Posts Encouraging Third Quarter; No Change to Our Fair Value Estimate

Qiagen reported strong third-quarter results that give us more confidence that management can attain its growth and margin expansion goals, but we’re leaving our fair value estimate and no-moat rating unchanged. When adjusted for stock repurchases, management’s preliminary outlook for 6% to 7% revenue growth and an adjusted EPS of $1.25 to $1.27 is close to our current forecast since we already incorporate a slight growth acceleration and additional margin expansion in our model. Qiagen’s growth...

Michael Waterhouse

Qiagen Posts Encouraging Third Quarter; No Change to Our Fair Value Estimate

Qiagen reported strong third-quarter results that give us more confidence that management can attain its growth and margin expansion goals, but we’re leaving our fair value estimate and no-moat rating unchanged. When adjusted for stock repurchases, management’s preliminary outlook for 6% to 7% revenue growth and an adjusted EPS of $1.25 to $1.27 is close to our current forecast since we already incorporate a slight growth acceleration and additional margin expansion in our model. Qiagen’s growth...

Michael Waterhouse

Qiagen's molecular diagnostics business and restructuring efforts should improve earnings growth.

Qiagen reported strong third-quarter results that give us more confidence that management can attain its growth and margin expansion goals, but we’re leaving our fair value estimate and no-moat rating unchanged. When adjusted for stock repurchases, management’s preliminary outlook for 6% to 7% revenue growth and an adjusted EPS of $1.25 to $1.27 is close to our current forecast since we already incorporate a slight growth acceleration and additional margin expansion in our model. Qiagen’s growth...

ValuEngine Rating and Forecast Report for QGEN

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and useful report available. ValuEngine`s three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. Consensus EPS trend and Earnings Surprise statistics provide additional insights. Also, ValuEngine recommendation, Forecast analysis, Past performance, Evaluation and rankings, Comparison to industry, Comparison with peers, Analyst opinions, EPS consensus expectations, Company profil...

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

Qiagen – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Expert Corporate Governance Service (ECGS)

Qiagen - AGM 17 June 2019

In general, QIAGEN is in compliance with the Dutch regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 8b, it is proposed to re-appoint Mr. Håkan Björklund as Member of the supervisory board. Although Mr. Björklund is considered independent, ECGS has concerns over his aggregate time commitments. Mr. Björklund is serving as Chairman of the board of directors of Acino AG, QIAGEN N.V. and Swedish Orphan Biovitrum AB (all listed), which exceeds ECGS¶ guidelines. In view of concerns over aggregate time commitments, ECGS recommends to vote OPPOSE. Unde...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Bottoms-up view on developed int'l, part two Big Picture: Our outlook remains neutral on the MSCI ACWI ex-U.S. index (when priced in local currency) while horizontal consolidation continues. On the other hand, we are negative on broad global ex-U.S. markets when priced in USD... see charts below. In today's report we take a bottoms-up approach to developed ex-U.S. equities, highlighting stocks that present attractive buy opportunities at current levels. Specifically we present actionable stocks within the Communications, Health Care, Manufacturing, Materials, Technology, Transportation, and U...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Macro Vision: Sector Synopsis

Investors continue to prefer the stability of the U.S. relative to emerging markets. The decline in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets. We continue to monitor the following to assess the health of the U.S. market: • U.S. Dollar: The U.S. dollar remains the de-facto world currency and has aided the U.S. equity markets in staying a step above the malaise in global markets. However we would prefer to see stabilization in emerg...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch